Zhenguo Cheng
Overview
Explore the profile of Zhenguo Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang G, Wang Z, Cheng Z, Wang W, Lu S, Zhang Z, et al.
Nat Commun
. 2024 Oct;
15(1):8988.
PMID: 39419971
Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous. Our understanding of full molecular and immune landscape of ESCC remains limited, hindering the development of personalised therapeutic strategies. To address this,...
2.
Du B, Zhang Z, Jia L, Zhang H, Zhang S, Wang H, et al.
Sci Rep
. 2024 May;
14(1):12090.
PMID: 38802444
Micropeptides hidden in long non-coding RNAs (lncRNAs) have been uncovered to program various cell-biological changes associated with malignant transformation-glioblastoma (GBM) cascade. Here, we identified and characterized a novel hidden micropeptide...
3.
Liu F, Cheng Z, Li X, Li Y, Zhang H, Li J, et al.
Mol Ther Nucleic Acids
. 2024 May;
35(2):102203.
PMID: 38737921
[This corrects the article DOI: 10.1016/j.omtn.2017.07.005.].
4.
Wang L, Zhang L, Dunmall L, Wang Y, Fan Z, Cheng Z, et al.
Cancer Lett
. 2024 Apr;
591:216871.
PMID: 38604310
Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred to as "living...
5.
Liu M, Zhang R, Huang H, Liu P, Zhao X, Wu H, et al.
Adv Sci (Weinh)
. 2023 Nov;
11(5):e2303907.
PMID: 37997186
Despite being a new promising tool for cancer therapy, intravenous delivery of oncolytic viruses (OVs) is greatly limited by poor tumor targeting, rapid clearance in the blood, severe organ toxicity,...
6.
Pan S, Zhu J, Liu P, Wei Q, Zhang S, An W, et al.
Theranostics
. 2023 Sep;
13(14):5130-5150.
PMID: 37771777
Current clinical treatments for gastric cancer (GC), particularly advanced GC, lack infallible therapeutic targets. The 3'-untranslated region (3'-UTR) has attracted increasing attention as a drug target. and experiments were conducted...
7.
Zhou W, Miao J, Cheng Z, Wang Z, Wang J, Guo H, et al.
Mol Ther Oncolytics
. 2023 Sep;
30:216-226.
PMID: 37663131
CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy has been demonstrated as one of the most promising therapeutic strategies for treating B cell malignancies. However, it has shown limited...
8.
Wang L, Wang X, Wu Y, Wang J, Zhou W, Wang J, et al.
Cancer Lett
. 2023 Jul;
568:216303.
PMID: 37422126
Chimeric antigen receptor T cell immunotherapy has achieved promising therapeutic effects in the treatment of hematological malignancies. However, there are still many obstacles, including on-target off-tumor antigen expression, that prevent...
9.
Huang H, Liu M, Sun M, Duan S, Pan S, Liu P, et al.
ACS Nano
. 2023 Jun;
17(15):14461-14474.
PMID: 37367941
Intravenous administration of oncolytic adenoviruses (OVs) is a hopeful tumor therapeutic modality. However, the sharp clearance of OVs by the immune system dampens its effectiveness. Many studies have attempted to...
10.
Ban W, Sun M, Huang H, Huang W, Pan S, Liu P, et al.
Nat Commun
. 2023 May;
14(1):2933.
PMID: 37217527
Oncolytic adenovirus (Ad) infection promotes intracellular autophagy in tumors. This could kill cancer cells and contribute to Ads-mediated anticancer immunity. However, the low intratumoral content of intravenously delivered Ads could...